Natural Killer Cell Therapeutics Market Size to Reach USD 11,368.3 Million in 2032
The Natural Killer Cell Therapeutics Market size was USD 658.7 Million in 2024 and is expected to register a revenue CAGR of 42.7% during the forecast period
13th May, 2025 – Strong pipeline and clinical trial momentum is a key driver driving natural killer cell therapeutics market revenue growth. Natural killer (NK) cell-based immunotherapies are gaining popularity in the field of cancer treatment. Early clinical trials revealed positive results, as well as excellent product efficacy and safety. Recent advancements have considerably strengthened the therapeutic potential of NK cells by providing them with improved identification and cytotoxic capabilities.
On October 2024, ImmunityBio, Inc., an immunotherapy pioneer, revealed that the first patients have been dosed in an early phase to assess the potential of its CAR-NK cell therapy targeting CD-19 in the treatment of non-Hodgkin’s lymphoma (NHL). The phase 1 open label clinical trial was meant to enroll up to ten people and was taking place in Johannesburg, Pretoria, and Bloemfontein, South Africa.
NK cell-based medicines have demonstrated the potential to be effective and strategic medications in cancer management in the future. However, NK cell-based therapies continue to encounter several obstacles, including guaranteeing continuous in vivo multiplication and proliferation of NK cells due to their limited lifespan in patients, which leads to a short response duration.
Even though NK cell-based monoclonal antibodies have showed potential anticancer activity in patients with various tumor types, dose-limiting toxicities may need to be managed and improved for the patient safety profile. Furthermore, there are still significant challenges to CAR-NK’s success in clinics, such as CAR-transduction efficiency, cell expansion limitations, a dearth of accessible targets, and inadequate solid tumor removal.
Key Highlights:
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) segment is expected to register the fastest growth rate over the forecast period. Natural killer (NK) cells are a tiny subset of lymphocytes that are thought to be the most critical cells capable of inducing ADCC. They activate innate immune responses and regulate spontaneous cytotoxicity against tumor and virus-infected cells. Because of their potential to induce ADCC, NK cell effector properties can be used to treat certain cancers. Antibody-dependent tumor killing via NK mediation occurs through many avenues, including cytotoxic granule exocytosis, tumor necrosis factor (TNF) family death receptor signaling, and the release of pro-inflammatory cytokines including interferon-gamma (IFNγ).
- Cancer segment is expected to account for the largest market share in 2024. According to the National Center of Biological Information (NCBI), the annual incidence of new cases in both men and women is roughly 4.3 per 100,000 population, with over 20,000 cases reported in the United States alone. The median age upon diagnosis is approximately 68 years, with a higher prevalence among non-Hispanic Whites. Furthermore, males have a higher incidence than females, with a ratio of 5:3.
- North America accounted for the largest market revenue share in the natural killer cell therapeutics market in 2024 due to advancements in cell engineering technologies and advanced research and developments. On October 2024, MiNK Therapeutics, a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, and Autonomous Therapeutics, Inc., a leader in developing first-in-class, disease-activated RNA medicines, have announced a research collaboration to effectively target and treat metastatic tumors. This cooperation will combine Autonomous’ precise encrypted RNA (encRNA) technology with MiNK’s revolutionary iNKT cell treatments, MiNK-215, and agenT-797. The companies will evaluate these technologies in state-of-the-art metastatic solid tumor models.
- Some major companies in the market report include Nkarta, Inc., Artiva Biotherapeutics, MiNK Therapeutics, Indapta Therapeutics, ONK Therapeutics Limited, Dragonfly Therapeutics, Glycostem Therapautics B.V., NKGen Biotech, ImmunityBio, Senti Biosciences, Fate Therapeutics, NKGen Biotech, NKILT Therapeutics, NK:IO Limited, GT Biopharma, Inc., and Others.
- On February 2024, Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing novel immunotherapies, has announced a new clinical collaboration to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly’s TriNKET technology platform and the company’s lead clinical asset, with Trodelvy, Gilead’s Trop-2-directed antibody drug conjugate (ADC), in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC).
- On January 2024, NK CellTech Co., Ltd., a leading biotech business focused on the development of NK cellular therapeutics, stated that the FDA has cleared the clinical study of NK010, a non-genetically modified natural killer cell. The FDA has cleared NK010, the first non-genetically modified NK cells expanded from allogeneic peripheral blood cells (PBMC), for clinical trials in China. NK010 has several significant anti-tumor properties, including a broad spectrum and strong expression of NK cell activation receptors, as well as excellent purity, allowing it to treat a wide range of tumor types.
Unlock the key to transforming your business strategy with our Natural Killer Cell Therapeutics Market insights:
Navistrat Analytics has segmented natural killer cell therapeutics market size based on therapy type, source, approaches, indication, and end-use:
- Therapy Type Outlook (Revenue, USD Million; 2022-2032)
- Allogeneic NK Cell Therapy
- Autologous NK Cell Therapy
- CAR-NK Cell Therapy
- Source Outlook (Revenue, USD Million; 2022-2032)
- Peripheral Blood
- Umbilical Cord Blood
- Induced Pluripotent Stem Cell (iPSC)
- NK Cell Lines
- Approaches Outlook (Revenue, USD Million; 2022-2032)
- Bispecific Antibodies
- Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
- Indication Outlook (Revenue, USD Million; 2022-2032)
- Cancer
- Hematologic Malignancies
- Solid Tumors
- Infectious Diseases
- CMV
- HIV
- Hepatitis
- Others
- Autoimmune and Inflammatory Disorders
- Others
- Cancer
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Hospitals & Cancer Treatment Centers
- Research Institutes & Academic Centers
- Biopharmaceutical & Cell Therapy Companies
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America